Clinical trial
FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian…
NCT00085527 · University of Chicago, Other · Withdrawn
Key facts
| NCT number | NCT00085527 |
|---|---|
| Title | FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer |
| Official title | A Phase II Study Of Depsipeptide In Patients With Relapsed Or Refractory Ovarian Carcinoma |
| Lead sponsor | University of Chicago, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | depsipeptide |
| Enrollment | 0 |
| Start date | May 1, 2005 |
| Primary completion | Sep 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Jun 11, 2004 |
| Last update posted | Sep 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: